Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Capobianco

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Degenerative Neurological and Neuromuscular Disease|July 17, 2020
Identifying responders and nonresponders to interferon therapy in multiple sclerosisLuca Prosperini, Marco Capobianco, Costanza Giannì
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 13, 2021
Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case reportMarco Capobianco, Antonio Bertolotto, Simona Malucchi
Neurology(R) Neuroimmunology & Neuroinflammation|January 6, 2017
Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective studyPaola Valentino, Fabiana Marnetto, Letizia Granieri, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|November 16, 2020
E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disordersThaís Armangue, Marco Capobianco, Aliénor de Chalus, et al.
Multiple Sclerosis and Related Disorders|December 10, 2020
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatmentFabio Giuseppe Masuccio, Marianna Lo Re, Antonio Bertolotto, et al.
Journal of Neuroimmunology|October 9, 2014
CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept studyFabiana Marnetto, Letizia Granieri, Paola Valentino, et al.
Molecular Biology Reports|March 13, 2022
The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubesSerena Martire, Paola Valentino, Fabiana Marnetto, et al.
Neurology and Therapy|June 18, 2020
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis PatientsAntonio Bertolotto, Serena Martire, Luca Mirabile, et al.
Dermatologic Therapy|July 3, 2020
Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosisFrancesca Di Tullio, Giulia Odorici, Claudia Lasagni, et al.
European Journal of Endocrinology|April 29, 2006
High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorptionAndrea Dovio, Laura Perazzolo, Laura Saba, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Degenerative Neurological and Neuromuscular Disease|July 17, 2020
Identifying responders and nonresponders to interferon therapy in multiple sclerosisLuca Prosperini, Marco Capobianco, Costanza Giannì
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 13, 2021
Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case reportMarco Capobianco, Antonio Bertolotto, Simona Malucchi
Neurology(R) Neuroimmunology & Neuroinflammation|January 6, 2017
Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective studyPaola Valentino, Fabiana Marnetto, Letizia Granieri, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|November 16, 2020
E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disordersThaís Armangue, Marco Capobianco, Aliénor de Chalus, et al.
Multiple Sclerosis and Related Disorders|December 10, 2020
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatmentFabio Giuseppe Masuccio, Marianna Lo Re, Antonio Bertolotto, et al.
Journal of Neuroimmunology|October 9, 2014
CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept studyFabiana Marnetto, Letizia Granieri, Paola Valentino, et al.
Molecular Biology Reports|March 13, 2022
The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubesSerena Martire, Paola Valentino, Fabiana Marnetto, et al.
Neurology and Therapy|June 18, 2020
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis PatientsAntonio Bertolotto, Serena Martire, Luca Mirabile, et al.
Dermatologic Therapy|July 3, 2020
Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosisFrancesca Di Tullio, Giulia Odorici, Claudia Lasagni, et al.
European Journal of Endocrinology|April 29, 2006
High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorptionAndrea Dovio, Laura Perazzolo, Laura Saba, et al.
Pageof 8